Which has better valuation and earnings, AMGN or ABBV?

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.69 $7.71B $14.37 26.98 AbbVie $61.16B 7.44 $4.23B $2.03 126.88

Is AMGN or ABBV more profitable?

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 20.96% 137.41% 13.28% AbbVie 5.79% -576.45% 13.39%

Does the media favor AMGN or ABBV?

In the previous week, AbbVie had 23 more articles in the media than Amgen. MarketBeat recorded 75 mentions for AbbVie and 52 mentions for Amgen. Amgen's average media sentiment score of 1.07 beat AbbVie's score of 0.95 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 33 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Is ABBV or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to AbbVie's net margin of 5.79%. Gilead Sciences' return on equity of 48.19% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Gilead Sciences 30.99% 48.19% 18.28%

Does the media prefer ABBV or GILD?

In the previous week, AbbVie had 19 more articles in the media than Gilead Sciences. MarketBeat recorded 75 mentions for AbbVie and 56 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat AbbVie's score of 0.95 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive Gilead Sciences 34 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ABBV or MRNA?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.44 $4.23B $2.03 126.88 Moderna $2.20B 10.43 -$2.82B -$8.15 N/A

Is ABBV or MRNA more profitable?

AbbVie has a net margin of 5.79% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Moderna -143.55% -26.64% -19.32%

Does the media refer more to ABBV or MRNA?

In the previous week, AbbVie had 54 more articles in the media than Moderna. MarketBeat recorded 75 mentions for AbbVie and 21 mentions for Moderna. AbbVie's average media sentiment score of 0.95 beat Moderna's score of 0.70 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive Moderna 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABT or ABBV?

In the previous week, AbbVie had 17 more articles in the media than Abbott Laboratories. MarketBeat recorded 75 mentions for AbbVie and 58 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.11 beat AbbVie's score of 0.95 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 40 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.44 $4.23B $2.03 126.88 Astrazeneca $58.74B 4.53 $10.23B $6.66 25.75

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Astrazeneca 17.02% 31.45% 13.20%

Does the media favor ABBV or AZN?

In the previous week, AbbVie had 18 more articles in the media than Astrazeneca. MarketBeat recorded 75 mentions for AbbVie and 57 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.17 beat AbbVie's score of 0.95 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 44 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive Astrazeneca 42 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: AbbVie will host a live Q2 2026 earnings call on July 31, 2026 at 9:00AM ET. Get details.

AbbVie (ABBV) Competitors

$257.57 -5.73 (-2.18%)

Closing price 07/30/2026 03:59 PM Eastern

Extended Trading

$254.60 -2.98 (-1.16%)

As of 04:54 AM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? MarketBeat compares AbbVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN).

How does AbbVie compare to Amgen?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.69	$7.71B	$14.37	26.98
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88

Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Amgen presently has a consensus target price of $357.00, indicating a potential downside of 7.90%. AbbVie has a consensus target price of $269.29, indicating a potential upside of 4.55%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
AbbVie	5.79%	-576.45%	13.39%

In the previous week, AbbVie had 23 more articles in the media than Amgen. MarketBeat recorded 75 mentions for AbbVie and 52 mentions for Amgen. Amgen's average media sentiment score of 1.07 beat AbbVie's score of 0.95 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	33 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

AbbVie beats Amgen on 10 of the 19 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

AbbVie (NYSE:ABBV) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

AbbVie presently has a consensus price target of $269.29, suggesting a potential upside of 4.55%. Gilead Sciences has a consensus price target of $157.93, suggesting a potential upside of 20.30%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has a net margin of 30.99% compared to AbbVie's net margin of 5.79%. Gilead Sciences' return on equity of 48.19% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Gilead Sciences	30.99%	48.19%	18.28%

In the previous week, AbbVie had 19 more articles in the media than Gilead Sciences. MarketBeat recorded 75 mentions for AbbVie and 56 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat AbbVie's score of 0.95 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Gilead Sciences	34 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has lower revenue, but higher earnings than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.89

Summary

Gilead Sciences beats AbbVie on 13 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

AbbVie (NYSE:ABBV) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, AbbVie had 54 more articles in the media than Moderna. MarketBeat recorded 75 mentions for AbbVie and 21 mentions for Moderna. AbbVie's average media sentiment score of 0.95 beat Moderna's score of 0.70 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Moderna	10 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie has a net margin of 5.79% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Moderna	-143.55%	-26.64%	-19.32%

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88
Moderna	$2.20B	10.43	-$2.82B	-$8.15	N/A

AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

AbbVie currently has a consensus price target of $269.29, suggesting a potential upside of 4.55%. Moderna has a consensus price target of $40.00, suggesting a potential downside of 30.94%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Summary

AbbVie beats Moderna on 12 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Abbott Laboratories has higher earnings, but lower revenue than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	4.13	$6.52B	$3.09	34.25
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88

Abbott Laboratories presently has a consensus target price of $118.17, indicating a potential upside of 11.67%. AbbVie has a consensus target price of $269.29, indicating a potential upside of 4.55%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Abbott Laboratories has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 54 consecutive years and AbbVie has raised its dividend for 53 consecutive years.

In the previous week, AbbVie had 17 more articles in the media than Abbott Laboratories. MarketBeat recorded 75 mentions for AbbVie and 58 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.11 beat AbbVie's score of 0.95 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	40 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Abbott Laboratories has a net margin of 11.65% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.69% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	11.65%	17.69%	9.44%
AbbVie	5.79%	-576.45%	13.39%

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats AbbVie on 14 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.44	$4.23B	$2.03	126.88
Astrazeneca	$58.74B	4.53	$10.23B	$6.66	25.75

70.2% of AbbVie shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AbbVie had 18 more articles in the media than Astrazeneca. MarketBeat recorded 75 mentions for AbbVie and 57 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.17 beat AbbVie's score of 0.95 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	44 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Astrazeneca	42 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Astrazeneca	17.02%	31.45%	13.20%

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.7%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AbbVie currently has a consensus target price of $269.29, indicating a potential upside of 4.55%. Astrazeneca has a consensus target price of $211.00, indicating a potential upside of 23.03%. Given Astrazeneca's higher possible upside, analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$465.20B	$341.58B	$7.04B	$23.53B
Dividend Yield	2.63%	2.59%	2.65%	4.19%
P/E Ratio	126.88	30.47	27.65	30.73
Price / Sales	7.44	5.45	490.18	81.99
Price / Cash	17.38	14.49	51.74	31.18
Price / Book	-140.75	8.34	10.05	4.66
Net Income	$4.23B	$11.61B	$3.60B	$1.07B
7 Day Performance	-0.59%	0.67%	0.67%	0.55%
1 Month Performance	2.43%	1.49%	-3.28%	1.58%
1 Year Performance	36.26%	36.69%	24.49%	17.66%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	4.143 of 5 stars	$257.57 -2.2%	$269.29 +4.5%	+35.8%	$465.20B	$61.16B	126.88	57,000	Trending News Analyst Forecast Options Volume Analyst Revision
AMGN Amgen	3.9925 of 5 stars	$375.20 +1.0%	$356.62 -5.0%	+28.6%	$202.97B	$36.75B	26.17	31,500	Trending News Upcoming Earnings Dividend Announcement Analyst Forecast Gap Down
GILD Gilead Sciences	4.9017 of 5 stars	$129.64 -0.9%	$158.33 +22.1%	+14.4%	$161.41B	$29.44B	17.71	17,000	Trending News Upcoming Earnings Analyst Forecast Analyst Revision Gap Down
MRNA Moderna	1.6244 of 5 stars	$54.13 -5.1%	$40.00 -26.1%	+80.2%	$21.46B	$1.94B	N/A	4,700	Gap Up
ABT Abbott Laboratories	4.422 of 5 stars	$103.10 +2.3%	$118.61 +15.0%	-17.7%	$179.50B	$44.33B	33.35	115,000	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors